0001104659-17-048994.txt : 20170802 0001104659-17-048994.hdr.sgml : 20170802 20170802182819 ACCESSION NUMBER: 0001104659-17-048994 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lavino Francesco Maria CENTRAL INDEX KEY: 0001711517 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 171001603 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2017-07-31 0 0001641640 Nabriva Therapeutics plc NBRV 0001711517 Lavino Francesco Maria 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 0 1 0 0 Chief Commercial Officer Stock Option 2017-07-31 4 A 0 150000 0.00 A 2027-07-31 Ordinary Shares 150000 150000 D The exercise price is Euro 8.94 per share. This option was granted on July 31, 2017. Vesting will begin on July 31, 2017 and end on July 31, 2021. Twenty-five percent (25%) of the option will vest on July 31, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. /s/ Robert Crotty, by power of attorney 2017-08-02